Candel Therapeutics, Inc.
CADLCIK 0001841387 · last filing Jul 8, 2026
Insider signal
trades dated in the last 90 days · non-derivative only
0 bought / 30,447 sold
net −30,447 sh · −$305.9K
- buys
- 0
- sells
- 2
- insiders active
- 2
Filing tape
Filed Wed, Jul 8, 2026
- ±0
Sims Mark E. — Chief Commercial Officer
- Granted285,000Stock Option (Right to Buy)→ 285,000 held
Filed Wed, Jul 1, 2026
- ±0
Loggia Nicoletta — Director
- Granted381Stock Option (Right to Buy)@ $8.64→ 381 held
- −7,000 sh · $70.2K
Tyagarajan Seshu — Chief Technology Officer
- Sold7,000Common Stock@ $10.02→ 83,865 held
- −23,447 sh · $235.8K
Barone Francesca — Chief Scientific Officer
- Sold23,447Common Stock@ $10.06→ 77,362 held
- ±0
Manning Paul B — Director
- Granted2,199Stock Option (Right to Buy)@ $8.64→ 2,199 held
- ±0
Papa Joseph C — Director
- Granted1,331Stock Option (Right to Buy)@ $8.64→ 1,331 held
Insiders on this tape
- Sims Mark E.Chief Commercial Officer
- Loggia NicolettaDirector
- Tyagarajan SeshuChief Technology Officer
- Barone FrancescaChief Scientific Officer
- Manning Paul BDirector
- Papa Joseph CDirector
Informational data only — not investment advice.
The institutional holdings shown here are aggregated from third-party public regulatory filings (such as SEC Form 13F). These filings are reported with a delay (generally up to 45 days after each quarter-end), are backward-looking, and may exclude short positions, non-U.S. holdings, cash, and other assets. The data may contain errors, omissions, misclassifications, or gaps, and may not reflect a manager's current positions.
All figures are provided on an "as is" basis for general information only. Nothing on this page is financial, investment, or trading advice, a recommendation, or an endorsement of any security, manager, or strategy. Do not rely on it. Independently verify any figure against the original filings and consult a qualified professional before making any financial decision. Your use is subject to our Terms of Service.